Inovio Pharmaceuticals Inc vs Global X Defense Tech ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Global X Defense Tech ETF trades at $69.69. The key difference: Global X Defense Tech ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SHLD | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Sector/Thematic |
52-Week High | $2.87 | $78.02 |
52-Week Low | $0.66 | $58.20 |
Enterprise Value | $49.56M | — |
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
SHLD, the Global X Defense Tech ETF, trades at $69.74, down slightly by 0.16% today. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI levels suggest overbought conditions. Recent news highlights increased institutional investment, with firms like Focus Financial Network raising stakes by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF benefits from global defense spending trends, including a $20 billion UK military overhaul (Zacks Investment Research, 2026-07-02).
The outlook for SHLD is positive, driven by rising global defense budgets and technological advancements in defense sectors. Investment opportunities include diversified exposure to defense innovation, supported by institutional accumulation. Risks involve geopolitical shifts, potential tariff impacts from policies like Trump's new tariffs (Fool - Investing News, 2026-08-04), and valuation pressures if growth slows. The ETF's performance hinges on sustained military expenditure increases and contract awards.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →